Results 21 to 30 of about 1,815 (184)

The sodium‐glucose co‐transporter 2 inhibitor tofogliflozin suppresses atherosclerosis through glucose lowering in ApoE‐deficient mice with streptozotocin‐induced diabetes

Pharmacology Research & Perspectives, 2022
Epidemiological and animal studies have revealed that sodium‐glucose cotransporter 2 (SGLT2) inhibitors suppress cardiovascular events in subjects with type 2 diabetes and atherosclerosis in animal models of diabetes. However, it still remains unclear if
Masahiko Iwamoto, Tetsuya Kubota, Yoshitaka Sakurai, Nobuhiro Wada, Seiji Shioda, Toshimasa Yamauchi, Takashi Kadowaki, Naoto Kubota   +7 more
doaj   +1 more source

Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

BMJ Open Diabetes Research & Care, 2021
Introduction The treatment of diabetes has a significant impact on the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We compared the effectiveness of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and pioglitazone for ...
Atsushi Nakajima, Takeharu Yamanaka, Yasushi Honda, Kento Imajo, Masataka Taguri, Masato Yoneda, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Anna Ozaki, Asako Nogami, Hiroyuki Kirikoshi, Tomoyuki Iwasaki, Takeo Kurihashi, Satoru Saito   +14 more
doaj   +1 more source

Effect of tofogliflozin on arterial stiffness in patients with type 2 diabetes: prespecified sub-analysis of the prospective, randomized, open-label, parallel-group comparative UTOPIA trial

Cardiovascular Diabetology, 2021
Background Tofogliflozin, an SGLT2 inhibitor, is associated with favorable metabolic effects, including improved glycemic control and serum lipid profile and decreased body weight, visceral adipose tissue, and blood pressure (BP).
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, On behalf of the UTOPIA study investigators   +26 more
doaj   +1 more source

The Impact of Tofogliflozin on Physiological and Hormonal Function, Serum Electrolytes, and Cardiac Diastolic Function in Elderly Japanese Patients with Type 2 Diabetes Mellitus [PDF]

, 2022
The sodium glucose transporter 2 (SGLT2) inhibitor tofogliflozin is a glucose-lowering drug that causes the excretion of surplus glucose by inhibiting SGLT2.
Fukuda, Akihiro, Hamada, Kazu, Higashikawa, Toshihiro, Iguchi, Masaharu, Ishigami, Keiichiro, Ito, Tomohiko, Izumida, Toshihide, Kanda, Tsugiyasu, Kasamaki, Yuji, Kiyosawa, Jun, Kuroki, Kengo, Maekawa, Naoto, Mizuno, Takurou, Nakahashi, Takeshi, Okuro, Masashi, Saito, Atsushi, Saito, Hitoshi, Sangen, Ryusho, Usuda, Daisuke, Yamada, Shinya   +19 more
core   +1 more source

Tofogliflozin long-term effects on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes mellitus lacking a history of cardiovascular disease: a 2-year extension study of the UTOPIA trial

Cardiovascular Diabetology, 2023
Background This study aimed to assess the long-term effects of tofogliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression and major clinical parameters in patients with type 2 diabetes lacking an apparent history of
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Akira Kurozumi, Masahiro Hatazaki, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Ken Kato, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA study investigators   +26 more
doaj   +1 more source

Suppressive effects of the sodium‑glucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice [PDF]

, 2020
岐阜大学(Gifu University)博士(医学)博士論文 (Doctoral dissertation)以下に掲載 Oncology Reports (2019) 42(6) p.2797-2805doctoral ...
398416, 加藤, 潤一
core   +1 more source

A decrease in plasma glucose levels is required for increased EGP with a single administration of an SGLT2 inhibitor tofogliflozin [PDF]

, 2021
順天堂大学博士（医学）2020年度doctoral ...
ヤマサキ, ノゾム, 山﨑, 望
core   +1 more source

Tofogliflozin: the road goes ever on [PDF]

Expert Opinion on Pharmacotherapy, 2014
Several drugs are available for the treatment of type 2 diabetes mellitus (T2DM), but few patients achieve and maintain glycaemic control without weight gain and hypoglycaemias. Sodium glucose co-transporter 2 (SGLT-2) inhibitors are an emerging class of drugs with an original mechanism of action involving inhibition of renal glucose reabsorption.
Kalliopi, Pafili, Nikolaos, Papanas
openaire   +2 more sources

非アルコール性脂肪性肝疾患モデルメダカの心筋病変に対する選択的PPARαモジュレーター、ナトリウム-グルコース共輸送体2阻害剤、スタチンの有効性の検討 [PDF]

, 2023
新潟大学Niigata University博士（医学）Objective: Nonalcoholic fatty liver disease (NAFLD) is associated with metabolic dysregulation and is linked with various cardiovascular complications, which often lead to poor prognostic outcomes.
Ohkoshi-Yamada, Marina, 大越, 麻理奈   +1 more
core   +1 more source

Influence of an SGLT2 inhibitor, tofogliflozin, on the resting heart rate in relation to adipose tissue insulin resistance [PDF]

, 2020
新潟大学博士(医学)Aims To examine the effects of a sodium–glucose co-transporter 2 (SGLT2) inhibitor, tofogliflozin, on resting heart rate by exploring baseline factors that independently influenced changes in the resting heart rate.
178229, Nojima, Toshiaki
core   +1 more source